A Multicenter Prospective Observational Study to Examine the Experience of Using Phosphocreatine in Combination Therapy for Heart Failure Caused by Cancer Treatment. Rationale and Design of the Study

Enhanced cancer treatment efficacy has resulted in a significant increase in the number of cancer survivors after the cure of malignant tumors. However, cardiovascular morbidity, including chronic heart failure, has become the leading cause of death and decreased life expectancy among cancer survivors. This is due, in particular, to the cardiotoxic effects of anticancer drugs and associated factors. Cardioprotective approaches aim to reduce the incidence and severity of cardiotoxicity through the use of cardioprotective agents (e.g., dexrazoxane), liposomal drug delivery systems (e.g., liposomal doxorubicin), and optimization of drug administration schedules. Reducing the cardiotoxicity of cancer treatments is a clinically important goal. Phosphocreatine-based therapy represents a potentially valuable new strategy in this area. In this regard, the study "Multicenter prospective observational study to investigate the experience of using phosphocreatine in combination therapy for heart failure caused by cancer treatment" was initiated. This publication presents the protocol of the observational non-interventional NEOCARD study.

1. Chlebowski RT. Adriamycin (doxorubicin) cardiotoxicity: a review. The Western Journal of Medicine. 1979;131(5):364–8. PMID: 394479

2. Alkofide H, Alnaim L, Alorf N, Alessa W, Bawazeer G. Cardiotoxicity and Cardiac Monitoring Among Anthracycline-Treated Cancer Patients: A Retrospective Cohort Study. Cancer Management and Research. 2021;13:5149–59. DOI: 10.2147/CMAR.S313874

3. Jain D, Aronow W. Cardiotoxicity of cancer chemotherapy in clinical practice. Hospital Practice. 2019;47(1):6–15. DOI: 10.1080/21548331.2018.1530831

4. Rhea IB, Oliveira GH. Cardiotoxicity of Novel Targeted Chemotherapeutic Agents. Current Treatment Options in Cardiovascular Medicine. 2018;20(7):53. DOI: 10.1007/s11936-018-0649-4

5. Dong J, Chen H. Cardiotoxicity of Anticancer Therapeutics. Frontiers in Cardiovascular Medicine. 2018;5:9. DOI: 10.3389/fcvm.2018.00009

6. Johnson CB, Davis MK, Law A, Sulpher J. Shared Risk Factors for Cardiovascular Disease and Cancer: Implications for Preventive Health and Clinical Care in Oncology Patients. Canadian Journal of Cardiology. 2016;32(7):900–7. DOI: 10.1016/j.cjca.2016.04.008

7. Perez IE, Taveras Alam S, Hernandez GA, Sancassani R. Cancer Therapy-Related Cardiac Dysfunction: An Overview for the Clinician. Clinical Medicine Insights: Cardiology. 2019;13:117954681986644. DOI: 10.1177/1179546819866445

8. Richards MA. The National Awareness and Early Diagnosis Initiative in England: assembling the evidence. British Journal of Cancer. 2009;101(S2):S1–4. DOI: 10.1038/sj.bjc.6605382

9. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treatment Reviews. 2011;37(4):300–11. DOI: 10.1016/j.ctrv.2010.11.001

10. Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Annals of Oncology. 2012;23(Suppl 7):vii155-166. DOI: 10.1093/annonc/mds293

11. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. The Lancet. 2007;370(9604):2011–9. DOI: 10.1016/S0140-6736(07)61865-0

12. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. The Oncologist. 2008;13(10):1084–96. DOI: 10.1634/theoncologist.2008-0120

13. Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. Journal of the American College of Cardiology. 2010;55(3):213–20. DOI: 10.1016/j.jacc.2009.03.095

14. Wells QS, Lenihan DJ. Reversibility of Left Ventricular Dysfunction Resulting from Chemotherapy: Can This Be Expected? Progress in Cardiovascular Diseases. 2010;53(2):140–8. DOI: 10.1016/j.pcad.2010.06.005

15. Chargari C, Kirov KM, Bollet MA, Magné N, Védrine L, Cremades S et al. Cardiac toxicity in breast cancer patients: From a fractional point of view to a global assessment. Cancer Treatment Reviews. 2011;37(4):321–30. DOI: 10.1016/j.ctrv.2010.08.007

16. Macedo AVS, Hajjar LA, Lyon AR, Nascimento BR, Putzu A, Rossi L et al. Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer. JACC: CardioOncology. 2019;1(1):68–79. DOI: 10.1016/j.jaccao.2019.08.003

17. De Baat EC, Mulder RL, Armenian S, Feijen EA, Grotenhuis H, Hudson MM et al. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database Systematic Reviews. 2022;9(9):CD014638. DOI: 10.1002/14651858.CD014638.pub2

18. Kalay N, Basar E, Ozdogru I, Er O, Cetinkaya Y, Dogan A et al. Protective Effects of Carvedilol Against Anthracycline-Induced Cardiomyopathy. Journal of the American College of Cardiology. 2006;48(11):2258– 62. DOI: 10.1016/j.jacc.2006.07.052

19. Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M et al. Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation. Journal of Clinical Oncology. 2010;28(25):3910–6. DOI: 10.1200/JCO.2009.27.3615

20. Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F et al. Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. Circulation. 2015;131(22):1981–8. DOI: 10.1161/CIRCULATIONAHA.114.013777

21. Cardinale D, Bacchiani G, Beggiato M, Colombo A, Cipolla CM. Strategies to Prevent and Treat Cardiovascular Risk in Cancer Patients. Seminars in Oncology. 2013;40(2):186–98. DOI: 10.1053/j.seminoncol.2013.01.008

22. Gulati G, Heck SL, Ree AH, Hoffmann P, Schulz-Menger J, Fagerland MW et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. European Heart Journal. 2016;37(21):1671–80. DOI: 10.1093/eurheartj/ehw022

23. Bosch X, Rovira M, Sitges M, Domènech A, Ortiz-Pérez JT, de Caralt TM et al. Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). Journal of the American College of Cardiology. 2013;61(23):2355–62. DOI: 10.1016/j.jacc.2013.02.072

24. Kciuk M, Gielecińska A, Mujwar S, Kołat D, Kałuzińska-Kołat Ż, Celik I et al. Doxorubicin – An Agent with Multiple Mechanisms of Anticancer Activity. Cells. 2023;12(4):659. DOI: 10.3390/cells12040659

25. Uusküla-Reimand L, Wilson MD. Untangling the roles of TOP2A and TOP2B in transcription and cancer. Science Advances. 2022;8(44):eadd4920. DOI: 10.1126/sciadv.add4920

26. Kong C-Y, Guo Z, Song P, Zhang X, Yuan Y-P, Teng T et al. Underlying the Mechanisms of Doxorubicin-Induced Acute Cardiotoxicity: Oxidative Stress and Cell Death. International Journal of Biological Sciences. 2022;18(2):760–70. DOI: 10.7150/ijbs.65258

27. D’Oria R, Schipani R, Leonardini A, Natalicchio A, Perrini S, Cignarelli A et al. The Role of Oxidative Stress in Cardiac Disease: From Physiological Response to Injury Factor. Oxidative Medicine and Cellular Longevity. 2020;2020:1–29. DOI: 10.1155/2020/5732956

28. Wu L, Wang L, Du Y, Zhang Y, Ren J. Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity. Trends in Pharmacological Sciences. 2023;44(1):34–49. DOI: 10.1016/j.tips.2022.10.003

29. Sharif SM, Hydock D. Insights into mitochondrial creatine kinase: examining preventive role of creatine supplement in doxorubicin-induced cardiotoxicity. Toxicology Mechanisms and Methods. 2025;35(2):136–45. DOI: 10.1080/15376516.2024.2393825

30. Derbugov V.N., Potapov A.L., Potievskaya V.I., Khmelevsky Ya.M. Exogenous Phosphocreatine Application in Elderly and Senile Patients Operated for Colorectal Cancer. General Reanimatology. 2017;13(4):38– 45. DOI: 10.15360/1813-9779-2017-4-38-45

31. Zhu Jing, Yao Hong-mei. Influence of creatine phosphate sodium on the quality of life of patients undergoing cancer chemotherapy. Hainan Medical Journal. 2012;23(16):31–6

32. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). European Heart Journal. 2022;43(41):4229–361. DOI: 10.1093/eurheartj/ehac244